Scarica l'app Stockscreener
1.71
1.16%
-0.02
Dopo l'orario di chiusura:
1.75
0.04
+2.34%
Precedente Chiudi:
$1.73
Aprire:
$1.75
Volume 24 ore:
5,067
Relative Volume:
0.03
Capitalizzazione di mercato:
$160.26M
Reddito:
$47.04M
Utile/perdita netta:
$-63.98M
Rapporto P/E:
-2.1205
EPS:
-0.8064
Flusso di cassa netto:
$-34.39M
1 W Prestazione:
-6.56%
1M Prestazione:
-1.72%
6M Prestazione:
-20.28%
1 anno Prestazione:
-14.50%
Intervallo 1D:
$1.706
$1.76
Intervallo di 1 settimana:
$1.706
$1.87
Portata 52W:
$1.63
$2.63
Innate Pharma Adr Stock (IPHA) Company Profile
Nome
Innate Pharma Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare IPHA vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.71 | 162.14M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | Iniziato | BTIG Research | Buy |
| 2021-09-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Iniziato | Goldman | Neutral |
Mostra tutto
Innate Pharma Adr Borsa (IPHA) Ultime notizie
Innate Pharma (NASDAQ:IPHA) Stock Price Down 2.2%Should You Sell? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Down 0.5%Here's What Happened - MarketBeat
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3% – Should You Buy? - Defense World
Innate Pharma (NASDAQ:IPHA) Shares Up 2.3%Should You Buy? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Up 3.7%Should You Buy? - MarketBeat
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress - Investing.com
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com India
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com UK
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewswire Inc.
Should I buy Innate Pharma (IPHA) - Zacks Investment Research
Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Down 3.9%Time to Sell? - MarketBeat
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com India
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) - Barchart.com
Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World
Innate Pharma FY2025 EPS Estimate Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral” - Defense World
Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners - Defense World
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Innate Pharma SA Reports First Half 2025 Financial Results - TipRanks
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway - Investing.com
Innate Pharma Reports First Half 2025 Business Update and Financial Results - Placera.se
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in August - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% HigherWhat's Next? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – Here’s What Happened - Defense World
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential By Investing.com - Investing.com South Africa
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
TuHURA Biosciences (HURA) Short Interest & Short Float | Updated Jan 2026 - MarketBeat
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
What Are Earnings Reports? - MarketBeat
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
AZN Stock Price and Chart — NASDAQ:AZN - TradingView
Earnings call: Innate Pharma reports progress in drug development - Investing.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Innate, Sanofi ink licensing deal for NK cells - MarketWatch
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Dec 2025 - MarketBeat
Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
Annovis Bio (ANVS) Short Interest Ratio and Volume 2025 - MarketBeat
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
Innate Pharma Adr Azioni (IPHA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.23%
1.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):